Street Calls of the Week
ACTON, Mass. - Insulet Corporation (NASDAQ:PODD) announced Thursday the appointment of Robert "Robbie" L. Huffines to its board of directors, effective October 31, 2025. Huffines, who previously served as Global Chair of Investment Banking at JP Morgan Chase & Co., will join as an independent director and serve on the board’s Audit Committee.
Huffines brings over three decades of experience in healthcare investment banking. His career at JP Morgan spanned from 1992 to 2024, where he held several leadership positions including co-head of the global healthcare investment banking group from 2002 to 2010, Vice Chairman of Investment Banking from 2011 to 2020, and Global Chair of Investment Banking from 2020 to 2024.
"Robbie brings more than three decades of distinguished experience advising healthcare companies at one of the world’s leading financial institutions," said Timothy Scannell, Chairman of the Board, in the company’s press release.
Prior to JP Morgan, Huffines worked at Alex Brown & Sons, focusing on equity financing and advisory for emerging growth companies. He holds an M.B.A. from the University of Virginia’s Darden School of Business and studied English and Economics at the University of North Carolina.
Huffines currently serves on the boards of Nextech Invest Ltd., Eikon Therapeutics, and the Hastings Center for Biomedical Ethics. He previously served as a director of Walgreens Boots Alliance until its sale in August 2025.
Insulet Corporation, headquartered in Massachusetts, specializes in tubeless insulin pump technology through its Omnipod brand of products for diabetes management. The company maintains strong liquidity with a current ratio of 2.26 and operates with moderate debt levels. InvestingPro analysis indicates the stock is trading near its Fair Value, with 12 additional exclusive insights available to subscribers. Detailed analysis of Insulet’s market position and growth prospects is available in the comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks.
In other recent news, Insulet Corporation has been the focus of several analyst firms and industry developments. Stifel has resumed coverage of Insulet with a Buy rating, highlighting strong growth momentum and projecting revenue and EBITDA estimates for 2026 and 2027 that exceed consensus expectations. Canaccord Genuity has increased its price target for Insulet to $399, citing advantages in the Type 2 Diabetes market and updated revenue guidance, projecting forward revenue estimates of $2.639 billion for 2025. Truist Securities has maintained its Buy rating and $365 price target, noting the company’s strong growth and announcing a transition in the Chief Financial Officer position, with the current CFO staying on as a Senior Advisor.
Additionally, Oppenheimer has initiated coverage on Insulet with an Outperform rating and a $365 price target, maintaining its previous positive outlook. Beyond financial assessments, Insulet has partnered with Pantone to introduce "Omnipod Mango," a new official color for its product line, aimed at distinguishing the brand in the medical device sector. These developments reflect a period of active engagement and strategic positioning for Insulet in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.